With a revenue increase of 68.55% in the first quarter 2026, year on year to cumulative value of $4 million, Crispr Therapeutics Ag's revenue per employee grew on a trailing twelve months basis to $ 20,413, this is below the company average. Within the Healthcare sector Employees of 160 other companies have achieved higher revenue per employee. While Crispr Therapeutics Ag's total ranking has deteriorated compared to the previous quarter from 838 to 1253. Crispr Therapeutics Ag has 201 employees.
Overview of Recent DevelopmentsCRISPR Therapeutics, a trailblazer in the realm of gene editing technologies, has recently made noteworthy progress in the treatment of severe genetic disorders, specifically sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The recent approval of its innovative therapy, CASGEVY (exagamglogene autotemcel), alongside the presentation of promising preliminary data for its drug CTX112 at the 2024 American Society of Hematology (ASH) Annual Meeting, underscores the company’s commitment to transforming patient care through groundbreaking therapies. However, despite these scientific advancements, CRISPR Therapeutics faces a dual challenge: operational efficiency and competitive performance.Key Highlights1. Strategic Milestones: - The launch of CASGEVY has gained momentum, reflecting the company’s strategic prioritization towards innovative therapies in genetic disorders. - The preliminary results of CTX112 indicate potential efficacy and safety, positioning the company as a front-runner in developing solutions for SCD and TDT.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
